- PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF
-
Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.
- -
-
Paragraph 0401; 0874-0876
(2020/01/08)
-
- MAP4K4 INHIBITORS
-
This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, f
- -
-
Paragraph 00206
(2019/05/02)
-
- PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS
-
New pyrazolopyridmiin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
- -
-
Page/Page column 91; 92
(2015/06/25)
-
- SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS
-
Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.
- -
-
Paragraph 0156; 0157
(2014/05/08)
-
- SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS
-
Provided are certain pyridopyrazine compounds, pharmaceutical compositions thereof and methods of use therefor.
- -
-
Page/Page column 34
(2013/02/27)
-
- AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME
-
The invention relates to novel azacarbonlines having formula (I), wherein: R3, R4 represent independently H; hal; CF3; substituted oxy, optionally substituted alkoxy; optionally substituted amino; substituted carbonyl; optionally substituted carboxyl; optionally substituted amide; sulphur, such as optionally substituted sulphones, sulphoxides or sulphides; linear, branched or cyclic C1-C10 alkyl optionally comprising an optionally substituted heteroatom; optionally substituted linear, branched or cyclic C2-C7 alkenyl; optionally substituted linear or branched C2-C6 alkynyl; optionally substituted aryl or heteroaryl; of which may be optionally substituted; in the form of a base or an acid addition salt. The invention also relates to the use of same in therapeutics for the treatment of cancer and to synthesis methods.
- -
-
Page/Page column 69
(2011/08/04)
-
- KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
-
The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
- -
-
Page/Page column 187-188
(2010/11/03)
-
- PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY
-
Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided her
- -
-
Page/Page column 46-47
(2010/02/15)
-
- Furanopyridine derivatives and methods of use
-
The present invention relates to furanopyridine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical composition
- -
-
Page/Page column 42; 48
(2010/10/20)
-
